@article { author = {Karimi Zarchi, Mojgan and Mehdizadeh Kashi, Abolfazl and Allahqoli, Leila and Sadat Tabatabai, Razieh and Shamsi, Farimah and Hashemian Asl, Nafiseh}, title = {The Recurrence and 5-Year Survival Rates in Patients with Borderline Ovarian Tumors in Yazd from 2006 to 2016}, journal = {Journal of Obstetrics, Gynecology and Cancer Research}, volume = {4}, number = {2}, pages = {57-61}, year = {2022}, publisher = {Farname Inc. (Science-Based Research Institute; Professional Publisher of Scientific Journals)}, issn = {2645-3991}, eissn = {2476-5848}, doi = {10.30699/jogcr.4.2.57}, abstract = { Background & Objective: This study investigated the recurrence and survival rates of patients with borderline ovarian tumors in Yazd in the last 10 years.  Materials & Methods: This census survival study was performed on 24 patients with borderline ovarian tumors who referred to hospitals affiliated to Yazd University of Medical Sciences from 2006 to 2016. A data collection checklist was used as a measurement tool and was completed by the researcher by reviewing the subjects’ medical records. The questionnaire included age, infertility, the number of delivery, contraceptive use, body mass index, time of diagnosis, time to start the treatment, whether alive or not, stage of the disease, the type of pathology, the type of surgery, and postoperative treatment. Data was analyzed by SPSS 16 using descriptive statistics.  Results: The mean age of these 24 patients was 33.58±10.61 and the mean recurrence time was 14±2 months. Sixteen (66.7%) patients had serous tumors and 8 (33.3%) patients had mucinous tumors. Among them, 18 (75%) patients underwent a hysterectomy, 2 (8.3%) patients underwent an oophorectomy and 4 (16.7%) patients underwent both total abdominal hysterectomy (TAH) and oophorectomy. Of the 24 studied patients, 4 patients (16.7%) received medicinal treatment (clomiphene citrate, HCG, HMG) after surgery. Three patients experienced recurrences, all in the contralateral ovary.  Conclusion: The recurrence time of epithelial borderline ovarian tumor was 14±2 months. There was no significant relationship between postoperative medicinal treatment and the recurrence rate.}, keywords = {Borderline Ovarian Tumor,Recurrence,Survival}, url = {https://www.jogcr.com/article_697175.html}, eprint = {https://www.jogcr.com/article_697175_b1a2ac53dcc7e8bdb91eccaa623ea126.pdf} }